NDA 017586 · Otsuka Icu Medcl
Normosol-R In Plastic Container
Magnesium Chloride, Potassium Chloride, Sodium Acetate, Sodium Chloride, Sodium Gluconate · Injection
Last checked: Nov 20, 2026Latest source record: Mar 22, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1975
Aug 13, 1975
Approved uses
1
Original approval plus efficacy supplements
Registered trials
9,299
2,122 Phase 3, 968 recruiting
FAERS reports
30
26 serious, 9 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 30, 2025.
INDICATIONS AND USAGE Normosol-R pH 7.4 is indicated for replacement of acute extracellular fluid volume losses in surgery, trauma, burns or shock. Normosol-R pH 7.4 also can be used as an adjunct to restore a decrease in circulatory volume in patients with moderate blood loss. Normosol-R pH 7.4 is not intended to supplant transfusion of whole blood or packed red cells in the presence of uncontrolled hemorrhage or severe reductions of red cell volume. Normosol-R pH 7.4 is particularly valuable as a solution for use in starting blood, i.e., as a priming solution for the infusion set. No hemolysis of blood is seen at the interface or with mixed solution and blood. It may also be used as a diluent to aid in the transfusion of packed red blood cells (PRBC). Normosol-R pH 7.4 and physiologic saline solution (0.9% Sodium Chloride Injection, USP) are compatible with both young and old PRBC.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 13, 1975 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
- NORMOSOL-R IN PLASTIC CONTAINER · MAGNESIUM CHLORIDE 30MG/100ML; POTASSIUM CHLORIDE 37MG/100ML; SODIUM ACETATE 222MG/100ML; SODIUM CHLORIDE 526MG/100ML; SODIUM GLUCONATE 502MG/100ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Chloride" as an intervention, any sponsor and status, largest first.
- Introduction of Cholera Vaccine in BangladeshPivotal-lookingCompleted
International Centre for Diarrhoeal Disease Research, BangladeshAcademic, hospital or other
NCT01339845 · 240,000 participants · Start Sep 2009 · Primary completion Dec 2016
Drug: ShanChol · For: Cholera
Sites: Dhaka, Bangladesh
- Vellore Typhoid Vaccine Impact TrialPivotal-lookingCompleted
Christian Medical College, Vellore, IndiaAcademic, hospital or other
NCT05500482 · 72,400 participants · Start May 1, 2023 · Primary completion Jan 31, 2026
Drug: Typhoid conjugate Vaccine · For: Typhoid Fever
Sites: Vellore, India
- Randomised Evaluation of COVID-19 TherapyPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04381936 · 70,000 participants (planned) · Start Mar 19, 2020 · Primary completion Sep 30, 2028
Drug: Lopinavir-Ritonavir; Corticosteroid and 20 more · For: Pneumonia
Sites: Brussels, Belgium; Tallinn, Estonia; Paris, France · 16 sites in all
- Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui ProvinceStatus unknown
Sinovac (Dalian) Vaccine Technology Co., Ltd.Industry
NCT05470855 · 45,400 participants (planned) · Start Jul 6, 2022 · Primary completion Nov 30, 2022
Drug: Live attenuated varicella vaccine · For: Varicella
Sites: Anqing, China; Chuzhou, China; Fuyang, China · 5 sites in all
- Crystalloid FLUID Choices for Resuscitation of Hospitalized PatientsPivotal-lookingCompleted
Ottawa Hospital Research InstituteAcademic, hospital or other
NCT04512950 · 43,626 participants · Start Aug 15, 2016 · Primary completion Jun 13, 2020
Drug: Ringer's lactate; 0.9% saline · For: Fluid Therapy
Sites: Hamilton, Canada; London, Canada; Ottawa, Canada · 7 sites in all
- Tranexamic Acid to Prevent Heavy Bleeding After Childbirth in Women at Higher RiskPivotal-lookingRecruiting
London School of Hygiene and Tropical MedicineAcademic, hospital or other
NCT05562609 · 40,000 participants (planned) · Start Apr 22, 2024 · Primary completion Sep 2027
Drug: Tranexamic acid · For: Postpartum Hemorrhage
Sites: Mbeya, Tanzania
- A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)Pivotal-lookingCompleted
WestVac Biopharma Co., Ltd.Industry
NCT04904471 · 39,663 participants · Start Jun 15, 2021 · Primary completion Jan 31, 2022
Drug: Recombinant COVID-19 vaccine (Sf9 cells) · For: COVID-19
Sites: Bekasi, Indonesia; Malang, Indonesia; Surabaya, Indonesia · 24 sites in all
Sinovac (Dalian) Vaccine Technology Co., Ltd.Industry
NCT05460429 · 37,920 participants (planned) · Start Jul 30, 2022 · Primary completion Mar 15, 2023
Drug: Live attenuated varicella vaccine · For: Varicella
Sites: Chuzhou, China; Lishui, China; Quzhou, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- metabolic acidosis5
- hyperkalaemia4
- acute kidney injury3
- hypoxia3
- sepsis3
- acute respiratory failure2
- ascites2
- cellulitis2
- fatigue2
- hyperglycaemia2
- intestinal perforation2
- paradoxical drug reaction2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 3 |
| 2016 | 6 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 10 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Balanced crystalloid solutions versus 0.9% saline for treating acute diarrhoea and severe dehydration in children.
Florez ID, Sierra J, Pérez-Gaxiola G · Cochrane Database Syst Rev 2023 · Meta-Analysis, Systematic Review
- Resuscitation with blood products in patients with trauma-related haemorrhagic shock receiving prehospital care (RePHILL): a multicentre, open-label, randomised, controlled, phase 3 trial.
Crombie N, Doughty HA, Bishop JRB, et al. · Lancet Haematol 2022 · Clinical Trial, Phase III, Multicenter Study
- Intravenous Calcium to Decrease Blood Loss During Intrapartum Cesarean Delivery: A Randomized Controlled Trial.
Ansari JR, Yarmosh A, Michel G, et al. · Obstet Gynecol 2024 · Randomized Controlled Trial, Equivalence Trial
- Fluid resuscitation with balanced electrolyte solutions results in faster resolution of diabetic ketoacidosis than with 0.9% saline in adults - A systematic review and meta-analysis.
Szabó GV, Szigetváry C, Turan C, et al. · Diabetes Metab Res Rev 2024 · Meta-Analysis, Systematic Review
- Antimicrobial dressings for the prevention of surgical-site infection: systematic review and meta-analysis.
Yusuf SM, James J, Chong B, et al. · Br J Surg 2026 · Systematic Review, Meta-Analysis
- Heparin Versus Saline: A Comparative Study to Support Practice Change Within an Organization.
Denke L, Allen M, Atem F, et al. · J Infus Nurs 2025 · Comparative Study, Randomized Controlled Trial
Sponsor: Otsuka
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.